Bridge Neurotech Raises $13.5M Seed Led by General Catalyst for Non-Invasive Brain-Computer Interface

Bridge Neurotech has raised $13.5 million in Seed funding, according to company funding data. The round was led by General Catalyst and included participation from Sunflower Capital, Scott Sandell, and reMind Capital.

What Bridge Neurotech Does

Bridge Neurotech is building a fully non-invasive, wearable brain-computer interface. The system reads brain activity through the skull using functional ultrasound imaging (fUSI) and AI-based neural decoding, removing the need for surgery or implants.

The company was founded in 2026 in Silicon Valley by CEO Will Biederman. Biederman developed the neural interface chip Neuralink used in its first devices and co-founded the nonprofit Forest Neurotech.

Bridge Neurotech is enrolling its first human research study in Redwood City, California. The company licenses Butterfly Network's Ultrasound-on-Chip technology under a multi-year Butterfly Embedded agreement.

Target Applications

Bridge Neurotech targets applications across:

• Neurological care
• Communication
• Human-computer interaction
• Consumer use

The Round at a Glance

• Company: Bridge Neurotech
• Round type: Seed
• Amount raised: $13.5 million USD
• Funding date: October 6, 2026
• Lead investor: General Catalyst
• Additional investors: Sunflower Capital, Scott Sandell, reMind Capital
• Stage: Seed

Why the Non-Invasive Approach Matters

The distinction between invasive and non-invasive brain-computer interfaces is central to Bridge Neurotech's positioning. Invasive systems require surgical implantation, which introduces clinical risk, regulatory complexity, and cost. Bridge Neurotech's approach instead reads neural activity through the skull, pairing functional ultrasound imaging with AI-based decoding.

The company's use of Butterfly Network's Ultrasound-on-Chip technology under a multi-year Butterfly Embedded agreement gives it access to an established chip platform rather than requiring it to develop imaging hardware from scratch.

Leadership and Track Record

CEO Will Biederman's background spans two notable organizations in the neurotechnology space. He developed the neural interface chip used in Neuralink's first devices, and he co-founded the nonprofit Forest Neurotech. That combination of commercial chip development and nonprofit research experience informs Bridge Neurotech's technical and clinical direction.

Clinical Milestone Ahead

The company is enrolling its first human research study in Redwood City, California. First-in-human research is a significant milestone for any neurotechnology company, and for a non-invasive platform it represents an opportunity to validate signal quality and decoding performance in real-world conditions.

What to Watch

For observers tracking the brain-computer interface sector, several elements of this Seed round stand out:

• Investor composition: General Catalyst led the round, with participation from Sunflower Capital, Scott Sandell, and reMind Capital.
• Technology differentiation: Functional ultrasound imaging plus AI-based neural decoding, delivered in a wearable form factor.
• Licensing strategy: A multi-year Butterfly Embedded agreement with Butterfly Network for Ultrasound-on-Chip technology.
• Application breadth: Stated targets span neurological care, communication, human-computer interaction, and consumer use.

Summary

Bridge Neurotech has closed a $13.5 million Seed round led by General Catalyst, with Sunflower Capital, Scott Sandell, and reMind Capital participating. The Silicon Valley company, founded in 2026 by CEO Will Biederman, is developing a fully non-invasive wearable brain-computer interface using functional ultrasound imaging and AI-based neural decoding. It licenses Butterfly Network's Ultrasound-on-Chip technology and is enrolling its first human research study in Redwood City, California.